A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505026-34-00

Acronym

NN6022-7683

Enrollment

Registered

2024-03-11

Start date

2024-03-26

Completion date

2025-02-17

Last updated

2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic diseases

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026